These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints. Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236 [TBL] [Abstract][Full Text] [Related]
3. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis. Brahmi M; Vinceneux A; Cassier PA Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289 [TBL] [Abstract][Full Text] [Related]
4. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Ravi V; Wang WL; Lewis VO Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109 [TBL] [Abstract][Full Text] [Related]
5. Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis). Lingamfelter M; Novaczyk ZB; Cheng EY JBJS Essent Surg Tech; 2022; 12(2):. PubMed ID: 36741035 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110 [TBL] [Abstract][Full Text] [Related]
8. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089 [TBL] [Abstract][Full Text] [Related]
9. Treatment of pigmented villonodular synovitis of the knee. Aurégan JC; Klouche S; Bohu Y; Lefèvre N; Herman S; Hardy P Arthroscopy; 2014 Oct; 30(10):1327-41. PubMed ID: 24999007 [TBL] [Abstract][Full Text] [Related]
10. Patient Outcomes After Resection of Pigmented Villonodular Synovitis in Patients in King Abdulaziz Medical City. Aljuhani W; Alamri A; Altorbak B; Alabbasi J; Ahmed F Cureus; 2024 Aug; 16(8):e68248. PubMed ID: 39347371 [TBL] [Abstract][Full Text] [Related]
13. Results and recurrence of pigmented villonodular synovitis of the ankle: does diffuse PVNS with extra-articular extension tend to recur more often? Guo Q; Shi W; Jiao C; Xie X; Jiang D; Hu Y Knee Surg Sports Traumatol Arthrosc; 2018 Oct; 26(10):3118-3123. PubMed ID: 28389877 [TBL] [Abstract][Full Text] [Related]
14. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095 [TBL] [Abstract][Full Text] [Related]